A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 31 Aug 2017 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
- 31 Aug 2017 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated